REG - Haleon PLC - Haleon 2024 Q3 Trading Statement

HALEONAnnouncement

31/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241031:nRSe3035Ka&default-theme=true

RNS Number : 3035K  Haleon PLC  31 October 2024

 

 

Haleon plc: 2024 Q3 Trading Statement

 

31 October 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today
announces its Q3 trading update for the year ending 31 December 2024 is
available at:
http://www.rns-pdf.londonstockexchange.com/rns/3035K_1-2024-10-30.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/3035K_1-2024-10-30.pdf)

 

The Q3 trading update will also be available on the Haleon website
www.haleon.com/investors (http://www.haleon.com/investors) , and the results
have been submitted in full unedited text to the Financial Conduct Authority's
National Storage Mechanism and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 

Presentation for analysts and shareholders

A short presentation followed by Q&A will be hosted by Tobias Hestler,
Chief Financial Officer at 9:00am GMT (10:00am CET) on 31 October 2024, which
can be accessed at www.haleon.com/investors/
(http://www.haleon.com/investors/) .

 

For analysts and shareholders wishing to ask questions on the Q&A call,
please use the dial-in details below which will have a Q&A facility:

 

 UK:         +44 800 358 1035
 US:         +1 855 979 6654
 All other:  +44 20 3936 2999
 Passcode:   401552

An archived webcast of the Q&A call will be available later on the day of
the results and can be accessed at www.haleon.com/investors
(http://www.haleon.com/investors) .

Amanda Mellor

Company Secretary

 

Enquiries

 

 Investors                                    Media

 Rakesh Patel            +44 7552 484646      Zoë Bird            +44 7736 746167
 Emma White              +44 7823 523562      Gemma Thomas        +44 7985 175048

 Email: investor-relations@haleon.com         Email: corporate.media@haleon.com

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans five major categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
Otrivin, Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  QRTQKKBNOBDDBKN